北约（“诺瓦得士”）试验中组织学分级、雌激素受体状态、事件及8年生存率之间的关系。
The relationship between histological grade, oestrogen receptor status, events and survival at 8 years in the NATO ('Nolvadex') trial.
作者信息
Singh L, Wilson A J, Baum M, Whimster W F, Birch I H, Jackson I M, Lowrey C, Palmer M K
机构信息
Department of Morbid Anatomy, Kings College Hospital School of Medicine and Dentistry, Denmark Hill, London, UK.
出版信息
Br J Cancer. 1988 Jun;57(6):612-4. doi: 10.1038/bjc.1988.139.
A pathological review was carried out on 600 patients with breast carcinoma entered into the 'Nolvadex' Adjuvant Trial Organisation (NATO) study. The tumours were graded histologically and these results were compared with the oestrogen receptor (ER) status of the tumours, the numbers of recurrences and the length of survival of the patients. It was found that histological grading was predictive both in terms of events and survival, and correlates significantly with oestrogen receptor status; within histological grades I and II, patients receiving 'Nolvadex' had fewer events and deaths compared with patients in the control group. For patients with grade III tumours qualitatively it was in the same direction as the benefit obtained in patients with grade I and II tumours.
对参加“诺瓦得士”辅助治疗试验组织（NATO）研究的600例乳腺癌患者进行了病理检查。对肿瘤进行了组织学分级，并将这些结果与肿瘤的雌激素受体（ER）状态、复发次数和患者的生存时间进行了比较。结果发现，组织学分级在事件和生存方面都具有预测性，并且与雌激素受体状态显著相关；在组织学I级和II级中，接受“诺瓦得士”治疗的患者与对照组患者相比，事件和死亡较少。对于III级肿瘤患者，定性结果与I级和II级肿瘤患者获得的益处方向相同。
Zotero 插件